A Phase 1 interventional study of BIBR 1048 MS low dose and BIBR 1048 MS medium dose in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-31.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Study to investigate and compare safety, pharmacokinetics and pharmacodynamics of BIBR 1048 MS following oral administration of single (150 mg, 220 mg and 300 mg) and multiple (150 mg and 220 mg q.d. and 150 mg b.i.d.) rising doses in healthy male subjects of Japanese and Caucasian origin.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy male subjects of Japanese or Caucasian origin according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate, respiratory rate and tympanic body temperature), 12- lead (electrocardiogram), clinical laboratory tests
Exclusion Criteria:
History of
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BIBR 1048 MS low dose
Drug: BIBR 1048 MS medium dose
Drug: BIBR 1048 MS high dose
Change in vital signs
Time frame: Baseline and up to day 26
Change in 12-lead electrocardiogram (ECG)
Time frame: Baseline and up to day 26
Change in clinical laboratory tests
Time frame: Baseline and up to day 26
Occurence of adverse events
Time frame: Up to day 26
Area under the curve (AUC) from 0-24 hours for activated partial thromboplastin time (aPTT)
Time frame: Day 1 and 12
AUC from 0-24 hours for ecarin clotting time (ECT)
Time frame: Day 1 and 12
Change in thrombin time (TT)
Time frame: Baseline and up to 72 hours after administration on day 1 and 12
Change in prothrombin time (PT) expressed as international normalised ratio (INR)
Time frame: Baseline and up to 72 hours after administration on day 1 and 12
Maximum value of aPTT
Time frame: Up to 72 hours after administration on day 1 and 12
Maximum value of ECT
Time frame: Up to 72 hours after administration on day 1 and 12
Change in ECT
Time frame: Baseline and up to 72 hours after administration on day 1 and 12
Change in aPTT
Time frame: Baseline and up to 72 hours after administration on day 1 and 12
Cmax (maximum measured concentration of the analyte in plasma)
Time frame: Up to 72 hours after administration on day 1
tmax (time from dosing to maximum measured concentration of the analyte in plasma)
Time frame: Up to 72 hours after administration on day 1
AUCτ,1 (area under the concentration-time curve of the analyte in plasma over a uniform dosing interval τ after administration of the single dose on day 1)
Time frame: Up to 72 hours after administration on day 1
AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable drug plasma concentration)
Time frame: Up to 72 hours after administration on day 1
AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)
Time frame: Up to 72 hours after administration on day 1
λz (terminal rate constant in plasma)
Time frame: Up to 72 hours after administration on day 1
t1/2 (terminal half-life of the analyte in plasma)
Time frame: Up to 72 hours after administration on day 1
MRTpo (mean residence time of the analyte in the body after po administration)
Time frame: Up to 72 hours after administration on day 1
CL/F (apparent clearance of the analyte in plasma following extravascular administration)
Time frame: Up to 72 hours after administration on day 1
Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular administration)
Time frame: Up to 72 hours after administration on day 1
Aet1-t2 (amount of analyte that is eliminated in urine from the time point t1 to time point t2)
Time frame: Up to 72 hours after administration on day 1
fet1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2)
Time frame: Up to 72 hours after administration on day 1
CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)
Time frame: Up to 72 hours after administration on day 1
Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ)
Time frame: Up to 72 hours after the last dose on day 12
tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state)
Time frame: Up to 72 hours after the last dose on day 12
Cmin,ss (minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ)
Time frame: Up to 72 hours after the last dose on day 12
AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)
Time frame: Up to 72 hours after the last dose on day 12
λz,ss (terminal rate constant in plasma at steady state)
Time frame: Up to 72 hours after the last dose on day 12
t1/2,ss (terminal half-life of the analyte in plasma at steady state)
Time frame: Up to 72 hours after the last dose on day 12
MRTpo,ss (mean residence time of the analyte in the body at steady state after po administration)
Time frame: Up to 72 hours after the last dose on day 12
CL/F,ss (apparent clearance of the analyte in the plasma at steady state after extravascular multiple dose administration)
Time frame: Up to 72 hours after the last dose on day 12
Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration)
Time frame: Up to 72 hours after the last dose on day 12
Aet1-t2,ss (amount of analyte that is eliminated in urine at steady state from the time point t1 to time point t2)
Time frame: Up to 72 hours after the last dose on day 12
fet1-t2,ss (fraction of analyte eliminated in urine at steady state from time point t1 to time point t2)
Time frame: Up to 72 hours after the last dose on day 12
CLR,t1-t2,ss (renal clearance of the analyte in plasma from the time point t1 until the time point t2 at steady state)
Time frame: Up to 72 hours after the last dose on day 12
Accumulation ratio RA,Cmax,7 based on Cmax
Time frame: Day 6 to day 15
Accumulation ratio RA,AUC,7 based on AUCτ (only for 150 mg and 220 mg q.d. groups)
Time frame: Day 6 to day 15
Linearity index (LI) based on AUC (only for 150 mg and 220 mg q.d. groups)
Time frame: Day 6 to day 15
No study locations are listed for this record.
The record gives a start of Dec 2004 and a primary completion of Jun 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dabigatran